Pancreatic Cancer Research

ResearcherUniversity of VeronaNo recent work listed

Marta Palmieri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1185-3469; OpenAlex author ID A5067979740. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 6 papers · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper

Papers 20

  1. Mitochondrial Elongation and OPA1 Play Crucial Roles during the Stemness Acquisition Process in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14143432↗
  2. Integrated lipidomics and proteomics reveal cardiolipin alterations, upregulation of HADHA and long chain fatty acids in pancreatic cancer stem cells. Co-author DOI 10.1038/s41598-021-92752-5↗
  3. Progressively De-Differentiated Pancreatic Cancer Cells Shift from Glycolysis to Oxidative Metabolism and Gain a Quiescent Stem State. Co-author DOI 10.3390/cells9071572↗
  4. Extracellular Matrix Composition Modulates the Responsiveness of Differentiated and Stem Pancreatic Cancer Cells to Lipophilic Derivate of Gemcitabine. Co-author DOI 10.3390/ijms22010029↗
  5. Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate-copper complex loaded into hyaluronic acid decorated liposomes. Co-author DOI 10.1016/j.bbagen.2018.09.018↗
  6. Extracellular matrix composition modulates PDAC parenchymal and stem cell plasticity and behavior through the secretome. Co-author DOI 10.1111/febs.14471↗
  7. Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways. Last author DOI 10.1016/j.jprot.2016.10.002↗
  8. Secretome protein signature of human pancreatic cancer stem-like cells. Co-author DOI 10.1016/j.jprot.2016.01.017↗
  9. Mitochondrial uncoupling protein 2 and pancreatic cancer: a new potential target therapy. Last author DOI 10.3748/wjg.v21.i11.3232↗
  10. Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi‑directionally convert into cancer stem cells. Last author DOI 10.3892/ijo.2014.2796↗
  11. Comparative proteomic and phosphoproteomic profiling of pancreatic adenocarcinoma cells treated with CB1 or CB2 agonists. Co-author DOI 10.1002/elps.201200402↗
  12. Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. Co-author DOI 10.1007/s10495-012-0790-6↗
  13. UCP2 inhibition triggers ROS-dependent nuclear translocation of GAPDH and autophagic cell death in pancreatic adenocarcinoma cells. Co-author DOI 10.1016/j.bbamcr.2012.10.028↗
  14. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. Last author DOI 10.1016/j.bbamem.2013.01.020↗
  15. Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. Last author DOI 10.1038/cddis.2013.151↗
  16. Roles for microRNA 23b in regulating autophagy and development of pancreatic adenocarcinoma. First author DOI 10.1053/j.gastro.2013.09.037↗
  17. Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. Co-author DOI 10.1016/j.ajpath.2012.07.016↗
  18. Proteomics in pancreatic cancer research. First author DOI 10.1002/pmic.201000401↗
  19. Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives. Last author DOI 10.1016/j.freeradbiomed.2011.01.001↗
  20. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Last author DOI 10.1038/cddis.2011.36↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ilaria Dando · 18 shared papers, 2011–2022 · strength 1.13
  2. Elisa Dalla Pozza · 17 shared papers, 2011–2022 · strength 1.08
  3. Massimo Donadelli · 12 shared papers, 2011–2020 · strength 0.56
  4. Daniela Cecconi · 7 shared papers, 2011–2021 · strength 0.47
  5. Jessica Brandi · 6 shared papers, 2013–2021 · strength 0.42
  6. Cristian Andres Carmona‐Carmona · 3 shared papers, 2020–2022 · strength 0.35
  7. Giulia Ambrosini · 3 shared papers, 2020–2022 · strength 0.35
  8. Aldo Scarpa Scarpa · 7 shared papers, 2011–2017 · strength 0.26
  9. Stefania Forciniti · 3 shared papers, 2018–2020 · strength 0.25
  10. Silvia Arpicco · 4 shared papers, 2011–2020 · strength 0.24
  11. Giulia Biondani · 4 shared papers, 2015–2018 · strength 0.23
  12. Claudia Di Carlo · 2 shared papers, 2020–2021 · strength 0.22
  13. Emílio Marengo · 2 shared papers, 2016–2021 · strength 0.18
  14. Maria Raffaella Greco · 2 shared papers, 2018–2020 · strength 0.17
  15. Stephan J. Reshkin · 2 shared papers, 2018–2020 · strength 0.17
  16. Rosa Angela Cardone · 2 shared papers, 2018–2020 · strength 0.17
  17. Eithne Costello · 2 shared papers, 2016–2017 · strength 0.11
  18. Raffaella Pacchiana · 1 shared paper, 2020 · strength 0.09
  19. Tiago M. A. Carvalho · 1 shared paper, 2020 · strength 0.09
  20. Alessandro Marengo · 1 shared paper, 2019 · strength 0.09
  21. Christopher Heeschen · 1 shared paper, 2019 · strength 0.09
  22. Claudia Fiorini · 2 shared papers, 2013 · strength 0.08
  23. Stefania Cannone · 1 shared paper, 2018 · strength 0.07
  24. Katrine Zeeberg · 1 shared paper, 2018 · strength 0.07
  25. Matteo Fassan · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.